UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (date of earliest event reported): June 23, 2021

 

USA EQUITIES CORP.

(Exact Name of Registrant as Specified in its Charter)

 

0-19041

(Commission File No.)

 

Delaware   30-1104301
(State of Incorporation)   (I.R.S. Employer Identification No.)

 

901 Northpoint Parkway Suite 302 West Palm Beach FL 33407   33407
(Address of Principal Executive Offices)   (ZIP Code)

 

Registrant’s telephone number, including area code: (929) 379-6503

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, $0.0001 par value   USAQ   OTCMKTS

 

 

 

 

 

 

This Current Report and other reports filed by the Company with the Securities and Exchange Commission (the “SEC”) contain or may contain forward-looking statements and information that are based upon beliefs of, and information currently available to, the Company’s management as well as estimates and assumptions made by the Company’s management. Such statements reflect the current view of the Company’s management with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the Company’s industry, operations and results of operations. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those reflected in forward-looking statements. Except as required by law, the Company does not intend to update any forward-looking statements to conform these statements to actual results.

 

ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

 

On June 23, 2021, USA Equities Corp. (the “Company,” “we,” “us” and words of similar import) entered into a Purchase Agreement with MedScience Research Group, Inc. pursuant to which we acquired the trademark “AllergiEnd,” the web domain “AllergiEnd.com” and the US Method Patent Registration No. 9,655,556 relating to the allergy testing kit and related materials we distribute to our physician clients. (collectively, the “Assets”). Each of the Assets is associated with the AllergiEnd® diagnostic and allergen immunotherapy products we currently distribute as part of our recurring revenue business model focused on non-allergy specialist medical practitioners. In consideration for the Assets we issued to MedScience one million two hundred fifty thousand (1,250,000) shares of our common stock and our promissory note in the amount of $750,000 bearing interest at the rate of ten percent (10%) per annum and payable in thirty-six consecutive monthly instalments commencing July 7, 2021 and continuing through June 7, 2024.

 

Concurrent with the execution and delivery of the Purchase Agreement with MedScience we entered into a Contract Manufacturing Agreement with MedScience whereby MedScience agreed to manufacture and supply to us certain allergy related products including test kits, immunotherapies and injectable mixtures on the terms and conditions set forth in the Manufacturing Contract for the ten-year term of the Agreement. The price for each product can be increased by MedScience at any time and from time to time on ninety (90) days’ notice to us.

 

Troy Grogan, our President and principal shareholder, is a director of MedScience and a holder of shares of common stock of MedScience.

 

The foregoing description of the Purchase Agreement, the promissory note issued to MedScience and the Manufacturing Contract does not purport to be complete and is qualified in its entirety by reference to the copies of the Purchase Agreement, the promissory note and the Manufacturing Contract included as Exhibits 10.1, 10.2 and 10.3 to this Current Report on Form 8-K which are incorporated herein by reference.

 

ITEM 2.01 COMPLETION OF ACQUISITION OR DISPOSITION OF ASSETS

 

See Item 1.01 hereof for a description of the assets we acquired from MedScience Research Group, Inc. on June 23, 2021 pursuant to a Purchase Agreement entered into on such date.

 

ITEM 3.02 UNREGISTERED SALES OF EQUITY SECURITIES

 

On June 23, 2021, we issued one million two hundred fifty thousand (1,250,000) shares of our common stock to MedScience Research Group, Inc., in consideration of the Assets acquired by us as described under Item 1.01 of this Report. The issuance was exempt under Section 4(2) of the Securities Act of 1933, as amended. The issuance was part of a private transaction in which no securities were offered to any party other than MedScience which accepted the shares as part of the consideration for the assets we acquired, no solicitation of any party was made in connection with the issuance, MedScience was advised that the shares had not been registered under the Securities Act and cannot be transferred unless they are registered for sale under the Securities Act or there is available an exemption from such registration requirements and appropriate “stop transfer” orders have been placed against the shares.

 

 

 

 

Item 7.01 REGULATION FD DISCLOSURE

 

On June 24, 2021, USA Equities Corp. (the “Company”) issued a press release entitled “USA Equities Corp. Acquires AllergiEnd® Assets.”

 

A copy of the above-mentioned press release is attached herewith as Exhibit 99.1.

 

By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD. The Company uses, and will continue to use, its website (https://usaqcorp.com), press releases, and various social media channels, including its Twitter account (https://twitter.com/USAQcorp), its LinkedIn account (https://www.linkedin.com/company/usaqcorp) its Facebook account (https://www.facebook.com/USA-Equities-100113722270622), and its Instagram account (https://www.instagram.com/usaqcorp/) as additional means of disclosing public information to investors, the media and others interested in the Company. It is possible that certain information that the Company posts on its website, disseminates in press releases and on social media could be deemed to be material information, and the Company encourages investors, the media and others interested in the Company to review the business and financial information that the Company posts on its website, disseminates in press releases and on the social media channels identified above, as such information could be deemed to be material information.

 

Exhibit No.   Description
     
10.1  

Purchase Agreement by and between USA Equites Corp. and MedScience Research Group, Inc., dated June 23, 2021.

10.2   Promissory Note Agreement by and between USA Equites Corp. and MedScience Research Group, Inc., dated June 23, 2021.
10.3   Manufacturing Agreement by and between USA Equites Corp. and MedScience Research Group, Inc., dated June 23, 2021. Portions of the Manufacturing Agreement containing pricing information have been omitted.
99.1  

Press release dated June 24, 2021 entitled “USA Equities Corp. Acquires AllergiEnd® Assets”

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this current report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: June 24, 2021  
     
USA Equities Corp.  
     
  /s/: Troy Grogan  
Name: Troy Grogan  
Title: CEO and Chairman  

 

 

 

 

Exhibit 10.1

 

PURCHASE AGREEMENT

 

THIS PURCHASE AGREEMENT (the “Agreement”), dated as of the 23rd day of June, 2021, by and between USA Equities Corp., with its principal place of business at 901 Northpoint Parkway Suite 302, West Palm Beach FL 33407 (the “Buyer”) and MedScience Research Group, Inc., a Florida corporation with its principal place of business at 16469 Bridlewood Cir Delray Beach FL 33445 the “Seller”). The Buyer and the Seller are sometimes referred to herein individually, as the “Party” and collectively, as the “Parties.”

 

WHEREAS, the Seller owns the US Trademark “AllergiEnd”, Registration No. 4,618,114 (the “Mark”), the Web domain “AllergiEnd.com” (the “Domain”), the US Method Patent Registration No. 9,655,556 (the “Patent”), together with the know-how and intellectual property related to the inventions embodied in the Patent, together Seller’s “Intellectual Property”; and

 

WHEREAS the Buyer wishes to purchase and the Seller desires to sell, transfer and assign said Intellectual Property for the consideration set forth in Article 2 below.

 

NOW, THEREFORE, in consideration of the foregoing premises and the mutual representations, warranties, covenants, and agreements contained herein, the adequacy and legal sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

 

ARTICLE 1

TRANSFER of ASSETS

 

1.1 Transfer.

 

(a) Seller hereby sells, assigns, transfers and delivers all right, title and interest of Seller in the Intellectual Property as set forth above, as well as the goodwill associated with the Mark (collectively, the “Purchased Assets”) to Buyer, in each case free and clear of all liens, claims and encumbrances as defined below.

 

(b) Concurrently herewith Seller is delivering to Buyer a Bill of Sale for the Purchased Assets. Promptly after the date hereof Seller shall execute and deliver such further instruments including a trademark assignment and patent assignment in such forms as are required to transfer record ownership of the Mark and Patent to Buyer on the records of the US Patent and Trademark Office and shall execute and deliver such additional documents, instruments, conveyances and assurances and take such further actions as may be reasonably required to carry out the intent of this Agreement so as to give full effect to the transactions contemplated by this Agreement.

 

 

 

 

ARTICLE 2

CONSIDERATION

 

2.1 Consideration.

 

In consideration for acquiring the Purchased Assets from Seller, at the Closing Buyer is delivering to Seller Buyer’s promissory note in the amount of $750,000. The note shall bear simple interest at the rate of ten percent (10%) per annum (the “Note”) and shall be payable in thirty-six consecutive equal monthly installments commencing the month following the date hereof. In addition, Buyer shall promptly after the date hereof issue to Seller or its designees one million two hundred fifty thousand (1,250,000) restricted shares of Buyer’s common stock, having a par value of $0.0001 (the “Shares”). Seller acknowledges that the Shares have not as yet been registered under the Securities Act of 1933, as amended, and the certificate(s) shall bear a restrictive legend. Upon issuance pursuant hereto, the Shares shall be duly issued, fully paid for and non-assessable.

 

ARTICLE 3

SELLER’ REPRESENTATIONS AND WARRANTIES

 

The Seller hereby represents and warrants to Buyer as follows:

 

3.1 Organization, etc. Seller is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware. The Seller has all requisite power to own, lease and operate all of its respective assets owned by it in connection with the conduct of its business, as well as to sell, transfer and assign the herein described Purchased Assets.

 

3.2 Authorization. The Seller has all requisite power and authority to enter into, execute, deliver, and perform its obligations under this Agreement and those other agreements and instruments required to be executed or delivered under this Agreement, and to perform its obligations thereunder.

 

3.3 Good Title. The Seller owns the Purchased Assets and is delivering to Buyer, good, valid and marketable title to the Purchased Assets, free and clear of all mortgages, pledges, security interests, liens (including tax liens), charges, options or other encumbrances of any nature whatsoever (collectively, the “Encumbrances”).

 

3.4 Consents and Approvals. No consent, approval, order or authorization of or from, or registration, notification, declaration or filing with any individual or entity is required in connection with the performance of this Agreement by the Seller or the consummation by the Seller and Buyer of the transactions contemplated herein.

 

ARTICLE 4

BUYER’S REPRESENTATIONS AND WARRANTIES

 

Buyer hereby represents and warrants to the Seller as follows:

 

4.1 Authorization and Power. Buyer has all power and authority to enter into this Agreement and to carry out the transactions contemplated herein. This Agreement is the valid and binding legal obligation of Buyer enforceable against Buyer in accordance with its terms.

 

 

 

 

4.2 Good Standing. The Buyer is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware with the requisite corporate power and authority to carry on its business as it is now being conducted and to own, operate and lease its properties and assets.

 

4.3 Authorization. The Buyer has all requisite power and authority to enter into, execute, deliver, and perform its obligations under this Agreement and those other agreements and instruments required to be executed or delivered under this Agreement, and to perform its obligations thereunder.

 

4.4 Non-Contravention. Neither the execution, delivery nor performance of this Agreement and each other transaction document nor the consummation of the transactions contemplated hereby or thereby will be in conflict with, or constitute a default, however defined (or an event which, with the giving of due notice or lapse of time, or both, would constitute such a default), under any agreement to which Buyer is a party; or violate any law.

 

4.5 Consents and Approvals. No consent is required by any person or entity in connection with the execution, delivery and performance by Buyer of its obligation under the Agreement or the consummation of the transactions contemplated herein.

 

ARTICLE 5

INDEMNIFICATION

 

5.1 Survival of Representations and Warranties. The representations and warranties of the Parties contained herein or in any signed writing delivered in connection with this Agreement will survive for a period of one (1) year after the execution of this Agreement.

 

5.2 Seller’s Indemnification. The Seller will indemnify Buyer and its officers, directors, agents and representatives, in their capacities as such, and the successors, heirs and personal representatives of any of them (collectively, the “Buyer Indemnified Parties”) against and hold them harmless from any and all damage, loss, liability and expense (including, without limitation, reasonable expenses of investigation and attorneys’ fees and expenses) (collectively “Loss”) incurred or suffered by any Buyer Indemnified Party arising out of or relating to any breach of any representation, warranty, covenant or other agreement of the Seller contained herein, provided a claim for indemnification is made within one year of the execution of this Agreement.

 

 

 

 

5.3 Buyer’s Indemnification. The Buyer will indemnify Seller and its officers, directors, agents and representatives, in their capacities as such, and the successors, heirs and personal representatives of any of them (collectively, the “Seller Indemnified Parties”) against and hold them harmless from any and all damage, loss, liability and expense (including, without limitation, reasonable expenses of investigation and attorneys’ fees and expenses) (collectively “Loss”) incurred or suffered by any Seller Indemnified Party arising out of or relating to any breach of any representation, warranty, covenant or other agreement of the Buyer contained herein, provided a claim for indemnification is made within one year of the execution of this Agreement.

 

ARTICLE 6

MISCELLANEOUS PROVISIONS

 

6.1 Expenses. Buyer and the Seller will each bear their own costs and expenses relating to the transactions contemplated hereby, including without limitation, fees and expenses of legal counsel, accountants, finders, consultants or other representatives for the services used, hired or connected with the transactions contemplated hereby. Neither Buyer nor any Seller will charge any of his expenses to any other Party or seek reimbursement from any Party for any of its expenses, except Buyer shall be responsible for all costs associated with the transfer and registration of any of the Intellectual Property with either the U.S. Patent and Trademark office or any other governmental agency involved with the registration and recognition of such properties.

 

6.2 Amendment and Modification. Subject to applicable law, this Agreement may be amended or modified by the Parties at any time with respect to any of the terms contained herein; provided, however, that all such amendments and modifications must be in writing duly executed by all of the Parties hereto.

 

6.3 Waiver of Compliance; Consents. Any failure of a Party to comply with any obligation, covenant, agreement or condition herein may be expressly waived in writing by the Party entitled hereby to such compliance, but such waiver or failure to insist upon strict compliance with such obligation, covenant, agreement or condition will not operate as a waiver of, or estoppel with respect to, any subsequent or other failure. No single or partial exercise of a right or remedy will preclude any other or further exercise thereof or of any other right or remedy hereunder. Whenever this Agreement requires or permits the consent by or on behalf of a Party, such consent will be given in writing in the same manner as for waivers of compliance.

 

6.4 No Third Party Beneficiaries. Nothing in this Agreement will entitle any person or entity (other than a Party hereto and its respective successors and assigns permitted hereby) to any claim, cause of action, remedy or right of any kind.

 

 

 

 

6.5 Notices. All notices, requests, demands and other communications required or permitted hereunder will be made in writing and will be deemed to have been duly given and effective: (i) on the date of delivery, if delivered personally; (ii) on the earlier of the fourth (4th) day after mailing or the date of the return receipt acknowledgement, if mailed, postage prepaid, by certified or registered mail, return receipt requested; or (iii) on the date of transmission, if sent by facsimile, telecopy, telegraph, telex or other similar telegraphic communications equipment, or to such other person or address as the Parties hereto in writing in accordance with this subsection, as follows:

 

  If to Buyer, then to:
   
  USA Equities Corp
  Attn: Troy Grogan, President
  901 Northpoint Parkway Suite 302 West Palm Beach FL 33407
  Telephone: (929) 379-6503
   
  If to Seller, then to:
   
  MedScience Research Group, Inc.
  Attn: Marvin Smollar, President
  16469 Bridlewood Cir Delray Beach FL 33445
  Telephone: (561) 515-5995

 

 

or to such other persons or addresses as Buyer and Seller will furnish to the other in writing in accordance with this Agreement.

 

6.6 Assignment. This Agreement and all of the provisions hereof will be binding upon and inure to the benefit of the Parties and their respective successors and permitted assigns, but neither this Agreement nor any of the rights, interests or obligations hereunder will be assigned (whether voluntarily, involuntarily, by operation of law or otherwise) by any Seller without the prior written consent of Buyer.

 

6.7 Governing Law. This Agreement will be governed by and construed in accordance with the laws of the State of Florida without regard to its conflict of law rules, principles or provisions of such state or of any other state. The sole jurisdiction and venue for any litigation arising out of this Agreement will be an appropriate federal or district court located in Palm Beach County of the State of Florida, and each Party hereby consents to such jurisdiction.

 

6.8 Counterparts. This Agreement may be executed simultaneously in one or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument.

 

6.9 Facsimile and Scanned Execution. Receipt by either Party of a counterpart of this Agreement manually signed and then scanned electronically and E-mailed to the other Party or manually signed and then sent by facsimile transmission to the other Party shall, for all purposes, be deemed to be an original counterpart with the same force and effect as the manually signed counterpart from which it was electronically reproduced.

 

6.10 Entire Agreement. This Agreement and the exhibits and other writings referred to in this Agreement or in any such exhibit or other writing are part of this Agreement, together they embody the entire agreement and understanding of the Parties hereto in respect of the transactions contemplated by this Agreement and together they are referred to as this Agreement or the transactions contemplated hereby. There are no restrictions, promises, warranties, agreements, covenants or undertakings, other than those expressly set forth or referred to in this Agreement. This Agreement supersedes all prior agreements and understandings between the Parties with respect to the transaction or transactions contemplated by this Agreement. Provisions of this Agreement will be interpreted to be valid and enforceable under applicable Law to the extent that such interpretation does not materially alter this Agreement; provided, however, that if any such provision becomes invalid or unenforceable under applicable Law such provision will be stricken to the extent necessary and the remainder of such provisions and the remainder of this Agreement will continue in full force and effect.

 

6.11 No Broker or Finder. Neither the Seller or Buyer has employed any broker, finder, investment banker or financial advisor or incurred any liability for any brokerage fee or commission, finder’s fee or financial advisory fee, in connection with the transactions contemplated hereby, nor is there any basis known to Seller or Buyer for any such fee or commission to be claimed by any person or entity.

 

(Signatures on Following Page)

 

 

 

 

USA Equities Corp as Buyer  
     
By: /s/ Troy Grogan  
Troy Grogan, as President and Principal Shareholder,  
Respectively  
     
Date: June 23, 2021  
     
MedScience Research Group, Inc., as Seller  
     
     
By: /s/ Marvin Smollar  
Marvin Smollar, President  
     
Date: June 23, 2021  

 

 

 

 

EXHIBIT 1

 

  US Method Patent “Method of Testing for Allergies” Number 9,655,556 B2
   
  US Trademark “AllergiEnd” Reg. No. 4,618,114
   
  Web Domain “AllergiEnd.com”

 

 

 

 

 

Exhibit 10.2

 

PROMISSORY NOTE

 

$750,000 June 23, 2021

 

FOR VALUE RECEIVED, USA Equities Corp. (the “Maker”), promises to pay to MedScience Research Group, Inc., a Florida corporation with its principal place of business at 16469 Bridlewood Circle, Delray Beach, Florida 33445, the principal sum of seven hundred fifty thousand ($750,000) dollars, together with interest thereon at the rate of ten per cent (10%) per annum, which shall be payable in thirty-six (36) equal consecutive monthly instalments of $24,200.39 commencing on the 7th day of July 2021 and continuing on the 7th day of each month thereafter, to and including June 7, 2024 (the “Maturity Date”).

 

Upon the occurrence and during the continuance of an Event of Default, Maker shall pay interest hereon at the rate of fifteen per cent (15%) per annum. In no event shall the Holder hereof, or any permitted successor or assign, be entitled to receive, collect or retain any amount of interest paid hereon in excess of that permitted by applicable law. The Maker shall have the right, at any time and from time to time, upon three business days’ notice to the Holder, to prepay this Note in whole or in part together with accrued interest on the amount prepaid, but without premium or penalty. All payments to Holder shall be made in United States dollars.

 

The Maker agrees to pay on demand all reasonable costs and expenses in connection with the preparation, execution, delivery, administration, modification, amendment and enforcement (whether through legal proceedings, negotiations or otherwise) of this Note and any other document to be delivered hereunder (such costs and expenses shall include without limitation, the reasonable fees and expenses of legal counsel.) The obligations of the Maker under this Paragraph shall survive the payment in full of this Note.

 

The occurrence of any of the following events shall constitute a default (“Event of Default”):

 

(i) Failure to Pay Principal or Interest. Maker fails to pay any installment of principal, interest or other sum due under this Note within ten (10) days of the due date thereof;

 

(ii) Receiver or Trustee. Maker or Guarantor shall make an assignment for the benefit of creditors or apply for or consent to the appointment of a receiver or trustee for it him, or for a substantial part of its or his property or business; or such a receiver or trustee shall otherwise be appointed without the consent of Maker of Guarantor and is not dismissed within sixty (60) days of appointment;

 

(iii) Bankruptcy. Bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings or relief under any bankruptcy law or any law, or the issuance of any notice in relation to such event, for the relief of debtors shall be instituted by or against Maker or Guarantor and if instituted against Maker or Guarantor are not dismissed within sixty (60) days of initiation; and

 

1
 

 

(iv) Judgements. One or more judgements for the payment of money in an aggregate amount in excess of $50,000 shall be rendered against the Maker and shall remain undischarged for ten days during which execution shall not be effectively stayed.

 

Upon the occurrence and during the continuance of any Event of Default, upon notice to Maker (except in the event of the failure to pay amounts due as provided above), the Holder may demand the payment of the unpaid principal amount due hereunder, which together with all interest accrued thereon and other amounts payable hereunder, shall become immediately due and payable, without presentment, demand, protest or notice of any kind, all of which are hereby expressly waived, and the Holder may immediately enforce any and all of the Holder’s rights and remedies provided herein or any other rights or remedies afforded by law.

 

The Maker hereby waives presentment for payment, demand, notice of dishonor and protest of this Note. This Note shall be governed by, and construed in accordance with, the laws of the State of Florida. None of the terms or provisions of this Note may be waived, altered, modified or amended except as the Holder may consent thereto in writing.

 

Without limiting the right of the Holder to bring any action or proceeding against the Maker or against property of the Maker arising out of or relating to this Note (an “Action”) in the courts of other jurisdictions, the Maker hereby irrevocably submits to the jurisdiction of any Florida or Federal Court sitting in Palm Beach County, Florida, respectively, and the Maker hereby irrevocably agrees that any Action may be heard and determined in any such State or Federal court.

 

Any notice or other communication required or permitted to be given to the Maker hereunder shall be in writing and shall be sent by Express Mail or by a recognized overnight delivery courier service to the Maker at 901 Northpoint Parkway Suite 302 West Palm Beach Florida 33407, Attn: President or to such other address as the Maker shall have furnished in writing in accordance with the provisions of this Note. Any notice or other communication given by the means permitted hereunder shall be deemed given and effective two days after deposit thereof with the United States Post Office or with a recognized overnight courier.

 

  USA Equities Corp.
     
  By:  /s/ Troy Grogan
    Troy Grogan
    President

 

2
 

 

Amortization Schedule

 

  1       7/7/2021     $ 750,000.00     $ 24,200.39     $ 17,950.39     $ 6,250.00     $ 732,049.61  
  2       8/7/2021     $ 732,049.61     $ 24,200.39     $ 18,099.98     $ 6,100.41     $ 713,949.63  
  3       9/7/2021     $ 713,949.63     $ 24,200.39     $ 18,250.81     $ 5,949.58     $ 695,698.82  
  4       10/7/2021     $ 695,698.82     $ 24,200.39     $ 18,402.90     $ 5,797.49     $ 677,295.92  
  5       11/7/2021     $ 677,295.92     $ 24,200.39     $ 18,556.26     $ 5,644.13     $ 658,739.66  
  6       12/7/2021     $ 658,739.66     $ 24,200.39     $ 18,710.89     $ 5,489.50     $ 640,028.77  
  7       1/7/2022     $ 640,028.77     $ 24,200.39     $ 18,866.82     $ 5,333.57     $ 621,161.95  
  8       2/7/2022     $ 621,161.95     $ 24,200.39     $ 19,024.04     $ 5,176.35     $ 602,137.91  
  9       3/7/2022     $ 602,137.91     $ 24,200.39     $ 19,182.57     $ 5,017.82     $ 582,955.34  
  10       4/7/2022     $ 582,955.34     $ 24,200.39     $ 19,342.43     $ 4,857.96     $ 563,612.91  
  11       5/7/2022     $ 563,612.91     $ 24,200.39     $ 19,503.62     $ 4,696.77     $ 544,109.29  
  12       6/7/2022     $ 544,109.29     $ 24,200.39     $ 19,666.15     $ 4,534.24     $ 524,443.15  
  13       7/7/2022     $ 524,443.15     $ 24,200.39     $ 19,830.03     $ 4,370.36     $ 504,613.12  
  14       8/7/2022     $ 504,613.12     $ 24,200.39     $ 19,995.28     $ 4,205.11     $ 484,617.84  
  15       9/7/2022     $ 484,617.84     $ 24,200.39     $ 20,161.91     $ 4,038.48     $ 464,455.93  
  16       10/7/2022     $ 464,455.93     $ 24,200.39     $ 20,329.92     $ 3,870.47     $ 444,126.00  
  17       11/7/2022     $ 444,126.00     $ 24,200.39     $ 20,499.34     $ 3,701.05     $ 423,626.66  
  18       12/7/2022     $ 423,626.66     $ 24,200.39     $ 20,670.17     $ 3,530.22     $ 402,956.49  
  19       1/7/2023     $ 402,956.49     $ 24,200.39     $ 20,842.42     $ 3,357.97     $ 382,114.07  
  20       2/7/2023     $ 382,114.07     $ 24,200.39     $ 21,016.11     $ 3,184.28     $ 361,097.97  
  21       3/7/2023     $ 361,097.97     $ 24,200.39     $ 21,191.24     $ 3,009.15     $ 339,906.73  
  22       4/7/2023     $ 339,906.73     $ 24,200.39     $ 21,367.83     $ 2,832.56     $ 318,538.89  
  23       5/7/2023     $ 318,538.89     $ 24,200.39     $ 21,545.90     $ 2,654.49     $ 296,992.99  
  24       6/7/2023     $ 296,992.99     $ 24,200.39     $ 21,725.45     $ 2,474.94     $ 275,267.54  
  25       7/7/2023     $ 275,267.54     $ 24,200.39     $ 21,906.49     $ 2,293.90     $ 253,361.05  
  26       8/7/2023     $ 253,361.05     $ 24,200.39     $ 22,089.05     $ 2,111.34     $ 231,272.00  
  27       9/7/2023     $ 231,272.00     $ 24,200.39     $ 22,273.12     $ 1,927.27     $ 208,998.88  
  28       10/7/2023     $ 208,998.88     $ 24,200.39     $ 22,458.73     $ 1,741.66     $ 186,540.15  
  29       11/7/2023     $ 186,540.15     $ 24,200.39     $ 22,645.89     $ 1,554.50     $ 163,894.26  
  30       12/7/2023     $ 163,894.26     $ 24,200.39     $ 22,834.60     $ 1,365.79     $ 141,059.65  
  31       1/7/2024     $ 141,059.65     $ 24,200.39     $ 23,024.89     $ 1,175.50     $ 118,034.76  
  32       2/7/2024     $ 118,034.76     $ 24,200.39     $ 23,216.77     $ 983.62     $ 94,817.99  
  33       3/7/2024     $ 94,817.99     $ 24,200.39     $ 23,410.24     $ 790.15     $ 71,407.75  
  34       4/7/2024     $ 71,407.75     $ 24,200.39     $ 23,605.33     $ 595.06     $ 47,802.42  
  35       5/7/2024     $ 47,802.42     $ 24,200.39     $ 23,802.04     $ 398.35     $ 24,000.39  
  36       6/7/2024     $ 24,000.39     $ 24,200.39     $ 24,000.39     $ 200.00     $ 0.00  

 

3

 

 

Exhibit 10.3

 

CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS HAVE BEEN MADE.

 

THIS CONTRACT MANUFACTURING AGREEMENT (this “Agreement”) is entered into effect as of the 23rd day of June, 2021 (the “Effective Date”) by and between MEDSCIENCE RESEARCH GROUP, INC., a Florida corporation (“Manufacturer”), and USA EQUITIES CORP, (“Product Owner”). Manufacturer and Product Owner are each referred to herein as a “Party” and collectively, the “Parties.”

 

RECITALS

 

WHEREAS, Manufacturer is in the business of manufacturing products related to allergy diagnostics and allergen immunotherapy systems and related components (all such products whether now or hereafter made available for sale by Manufacturer being hereinafter referred to as “Products”).

 

WHEREAS, Product Owner wishes Manufacturer to produce Products for sale by Product Owner.

 

NOW, THEREFORE, in consideration of the foregoing premises and the mutual representations and agreements set forth herein, and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Manufacturer and Product Owner, intending to be legally bound, hereby agree as follows:

 

1. PURCHASE ORDERS; PRICING.

 

A. Purchase Orders. Product Owner shall order Products in accordance with the terms and conditions of this Agreement. Each order for the purchase of Products (a “Purchase Order”) must be submitted to Manufacturer by Product Owner by email to the email address specified by Manufacturer. Each Purchase Order shall specify (i) the quantity of Products being ordered, (ii) the price to be paid by Product Owner to Manufacturer for the Products ordered, (iii) payment terms granted by Manufacturer, and (iv) the requested receipt date and delivery instructions for the applicable Products ordered. Receipt dates must be during the term of this Agreement, except Product Owner may request, subject to Manufacturer’s acceptance in Manufacturer’s sole and absolute discretion, a Purchase Order with a requested receipt date after the expiration or termination of this Agreement, in which case, if accepted by Manufacturer, the terms and conditions of this Agreement shall apply to such shipment, but under no circumstances should such shipment be deemed to be or construed as being a renewal or extension of this Agreement or the exclusivity rights granted to Product Owner herein. The Parties agree that to the extent that any of the terms and conditions of this Agreement conflict or are inconsistent with the terms or conditions of any Purchase Order submitted by Product Owner, the terms and conditions of this Agreement shall prevail and control to the extent of any such conflict or inconsistency, unless the Purchase Order containing such conflicting or inconsistent terms and conditions is countersigned by Manufacturer, in which case the terms and conditions set forth in such Purchase Order shall prevail and control to the extent of any such conflict or inconstancy.

 

The price to be paid for each Product is set forth on Exhibit A. Manufacturer shall not have the right to increase any price set forth on Schedule A without giving Product Owner 90 days prior notice of such increase.

 

 

 

 

B. Acceptance of Purchase Order. A Purchase Order submitted by Product Owner shall be deemed to have been accepted by, and shall be binding upon, Manufacturer when it is countersigned by Manufacturer or if it is not rejected by Manufacturer, in whole or in part, by written notice to Product Owner sent within five (5) business days of its receipt by Manufacturer. Notwithstanding anything contained herein to the contrary, Manufacturer may only reject, cancel, or delay any Purchase Order placed by Product Owner which it has been deemed to have accepted, pursuant to Section 3.B. below. In the event Manufacturer is unable to fill all of a Purchase Order for any reason, it shall promptly notify Product Owner and Product Owner shall have the right, in its discretion, to cancel the subject Purchase Order. Product Owner may change or cancel any of its Purchase Orders without penalty so long as Product Owner provides written notice to Manufacturer and the Products have not yet been shipped; provided that Product Owner shall pay to Manufacturer a fee of twenty five percent (25%) of the aggregate purchase price of the Products of which manufacturing has commenced that are subject to any Purchase Order which has been materially changed or canceled by Product Owner.

 

C. Invoices and Payment Terms. Manufacturer shall send Product Owner invoices via mail or email for each shipment. Product Owner shall notify Manufacturer in writing if Product Owner disputes any charges set forth on an invoice within fifteen (15) calendar days after receipt of such invoice, specifying in reasonable detail the items disputed and basis for the dispute. Thereafter, the Parties will work in good faith to resolve such dispute as quickly as is reasonably possible. If any such dispute is not resolved within sixty (60) calendar days after Product Owner’s receipt of the applicable invoice, then Manufacturer may refuse to accept any new Purchase orders under this Agreement until such time as the dispute is resolved and all amounts agreed upon by the Parties to be due are paid in full. All undisputed amounts on each invoice are due and payable within thirty (30) calendar days from the date of Product Owner’s receipt of the invoice. Payments due hereunder must be made, at Product Owner’s option, by ACH, wire transfer, certified check or such other method as may be agreed to by the Parties. Manufacturer reserves the right to change or modify payment terms upon sixty (60) calendar days’ written notice to Product Owner at any time following a default by Product Owner of its payment obligations under this Agreement with such changes or modifications to be effective for Purchase Orders submitted after such sixty (60) calendar day period. Invoices will be issued upon shipment of the product from Manufacturer’s warehouse or production facility to Product Owner or to Product Owner’s customer via direct shipment.

 

D. Past Due Amounts. If any undisputed amount due Manufacturer by Product Owner, for any reason, becomes past due, Manufacturer shall provide written notice to Product Owner and, if such amounts remain outstanding for fifteen (15) calendar days following receipt of such notice, Manufacturer may at its option and without further notice withhold further shipments or deliveries of Products under this Agreement until such past due invoices are paid in full.

 

E. Taxes. Product Owner shall be responsible for any national, state or local sales, use, value added, or other tax, tariff, duty or assessment levied or imposed by the United States or any foreign governmental authority arising out of or related to any of the transactions contemplated by this Agreement, including sales of Product to Product Owner, other than taxes based upon Manufacturer’s income. Product Owner must pay directly, or reimburse Manufacturer for the amount of such sales, use, value added or other tax, tariff, duty or assessment which Manufacturer is at any time obligated to pay or collect with respect to or arising out of the sale of Products under this Agreement.

 

 

 

 

2. SHIPMENTS; PRODUCTS.

 

A. Shipment Terms; Title and Risk of Loss. All Products purchased by Product Owner under this Agreement will be packaged for shipment in Manufacturer’s standard containers, marked for shipment in the case of any purchase by Product Owner of Products from Manufacturer for sale to Physician Customer at the address specified by Product Owner in the Purchase Order (the applicable destination being hereinafter referred to as the “Destination”). All costs of shipment shall be paid by Manufacturer for any purchase by Product Owner of Products from Manufacturer for sale to Physician Customers (and all such Products shall be directly shipped by Manufacturer to each such Physician Customer at the address specified by Product Owner in the applicable Purchase Order unless Product Owner requests that the Product be shipped to it). Title and risk of loss will pass F.O.B. Destination. For Products shipped to Product Owner, Product Owner shall be solely responsible for all costs of shipment for the subsequent sale by Product Owner to Physician Customers. Manufacturer shall ship Products on or before the requested receipt date designated in a Purchase Order (provided that such receipt date is not less than twenty (20) business days after the Purchase Order is received by Manufacturer) and shall promptly notify Product Owner when Manufacturer knows or has reason to believe that a shipment will not be delivered by the requested receipt date. Any expense for any special packaging or any special delivery requested by Product Owner shall be borne by Product Owner.

 

B. Manufacturer’s Right to Delay or Cancel. Notwithstanding Manufacturer’s obligations in this Agreement, Manufacturer may refuse, cancel or delay any shipment of Products when Product Owner is delinquent in any payment for more than (30) calendar days, or when Product Owner is in material breach of its obligations under this Agreement which has not been cured pursuant to Section 11.A.

 

C. Acceptance of Shipments. Product Owner shall have ten (10) business days from the date of arrival of the shipment of the Products at the applicable Destination or other shipping location agreed upon by the Parties to inspect the Products and notify Manufacturer in writing of any discrepancies with respect to such Products, including but not limited to any discrepancies in the quantity or quality of the Products. Products with respect to which Product Owner does not notify Manufacturer of any discrepancies in writing shall be deemed accepted by Product Owner.

 

3. INTELLECTUAL PROPERTY RIGHTS.

 

Manufacturer’s Marks. Unless otherwise directed by Product Owner, Products shall bear and shall be shipped in packaging bearing Manufacturer’s logos, trademarks, and trade names, and shall be accompanied by branding and marketing materials created by or on behalf of Manufacturer. Manufacturer shall give Product Owner ninety (90) days’ notice of Manufacturer’s intent to change the containers or packaging for Products or the logos, trademarks, and trade names, and branding and marketing materials used in connection with the Products. Manufacturer hereby grants to Product Owner a revocable, non-transferable, non-exclusive, limited license to use Manufacturer’s logos, trademarks, and trade names, together with all branding and marketing materials created by or on behalf of Manufacturer in connection with the Products, (collectively the “Manufacturer IP”), solely in connection with the marketing, advertisement and sale of the Products. Such license shall immediately terminate upon the expiration or termination of this Agreement. Product Owner shall strictly comply with all standards of use for the Manufacturer IP and must at all times display appropriate trademark and copyright notices as instructed by Manufacturer. Product Owner acknowledges and agrees that the Manufacturer IP and other intellectual property provided to Product Owner by Manufacturer, if any, are the sole and exclusive property of Manufacturer. Product Owner shall not acquire any right, title or interest under this Agreement in any patent, copyright, Manufacturer IP or other intellectual property right of any kind of Manufacturer. No implied license, patent, copyright or other intellectual property right of Manufacturer is granted under this Agreement or otherwise. During the term of this Agreement and thereafter, Product Owner shall not do anything that will in any manner infringe, impeach, dilute or lessen the value of the Manufacturer IP, patents, copyrights or other intellectual property of Manufacturer or the goodwill associated therewith or that will tend to prejudice the reputation of the Manufacturer or the sale of any Products.

 

 

 

 

4. CONFIDENTIAL INFORMATION.

 

A. Confidential Information. The Parties acknowledge and agree that during the term of this Agreement, each may receive confidential information from the other Party. “Confidential Information” shall mean (i) information relating to a Party’s and its affiliates’ products or business including, but not limited to, the business plans, financial records, customers, suppliers, products, product samples, strategies, inventions, procedures, sales aids or literature, technical data, advice or knowledge, contractual agreements, pricing, price lists, product white papers, plans, designs, specifications, and know-how or other intellectual property, that may be at any time furnished, communicated or delivered by either party to the other party whether in oral, tangible, electronic or other form and (ii) all other non-public information provided by one Party to the other including, but not limited, to financial, technical and business information, and all non-promotional materials furnished by one Party to another.

 

B. Exceptions. The “Receiving Party” shall not have any obligations to preserve the confidential nature of any Confidential Information that (a) Receiving Party can demonstrate by competent evidence was rightfully in the Receiving Party’s possession before receipt from the “Disclosing Party”; (b) is or becomes a matter of public knowledge through no fault of the Receiving Party; (c) is rightfully received by Receiving Party from a third party without, to the best of Receiving Party’s knowledge, a duty of confidentiality; (d) is independently developed by Receiving Party without use of the Confidential Information; or (e) is disclosed by Receiving Party with Disclosing Party’s prior written approval.

 

C. Use of Confidential Information; Standard of Care. The Receiving Party shall maintain the Confidential Information in confidence and disclose the Confidential Information only to its employees, subcontractors and consultants who have a need to know such Confidential Information in order to fulfill the business affairs and transactions between the Parties contemplated by this Agreement and who are under confidentiality obligations no less restrictive as, or who have been advised of the confidentiality obligations set forth in, this Agreement. The Receiving Party shall remain responsible for breaches of this Agreement arising from the acts of its employees, subcontractors and consultants to whom it provides the Disclosing Party’s Confidential information. The Receiving Party shall protect Confidential Information by using the same degree of care as Receiving Party uses to protect its own information of a like nature, but no less than a reasonable degree of care, to prevent the unauthorized use, disclosure, dissemination, or publication of the Confidential Information. The Receiving Party agrees not to use the Disclosing Party’s Confidential Information for its own purpose other than in connection with the transactions contemplated by this Agreement or for the benefit of any third party, without the prior written approval of the Disclosing Party. The Receiving Party shall promptly return or certify destruction of all copies of Confidential Information upon request by the Disclosing Party or upon the expiration or earlier termination of this Agreement.

 

D. Equitable Relief. The Receiving Party hereby agrees and acknowledges that any breach or threatened breach of this Agreement regarding the treatment of the Confidential Information may result in irreparable harm to the Disclosing Party for which there may be no adequate remedy at law. In addition to other remedies provided by law or at equity, in such event the Disclosing Party shall be entitled to seek an injunction, without bond, preventing any further breach of this Agreement by the Receiving Party.

 

 

 

 

5. INSURANCE. Manufacturer shall maintain, during the term of this Agreement, Commercial General Liability Insurance with minimum limits, including under any General Liability Umbrella Policies, of not less than $2,000,000 combined single limit for bodily injury and property damage on Products purchased by Product Owner for resale. Manufacturer shall use commercially reasonable efforts to provide Product Owner with thirty (30) calendar days’ prior written notice of any change or cancellation in any applicable insurance policies.

 

Product Owner shall maintain, during the term of this Agreement, Commercial General Liability Insurance with minimum limits, including under any General Liability Umbrella Policies, of not less than $2,000,000 combined single limit for bodily injury and property damage. Product Owner shall use commercially reasonable efforts to provide Manufacturer with thirty (30) calendar days’ prior written notice of any change or cancellation in any applicable insurance policies.

 

6. WARRANTY; RECALL.

 

A. Warranty. Manufacturer warrants to Product Owner, for a period of one year from the date of delivery by Manufacturer to the intended recipient thereof, that any Products delivered by Manufacturer pursuant to this Agreement shall conform in all material respects to Manufacturer’s written specifications for such Products, and shall be free of defects in materials and workmanship. Manufacturer further warrants to Product Owner that it has title to the Products to be conveyed hereunder and has the right to sell the same and that at the time of delivery, such Products shall be free of any security interest or other lien or any other encumbrances whatsoever (the warranties provided in the preceding two sentences being hereinafter referred to as the “Limited Warranty”). Except for the Limited Warranty, Manufacturer makes no warranties or representations to Product Owner or any other person with respect to the Products or any services provided to Product Owner or any other person. Manufacturer may not change any of the terms of the Limited Warranty at any time, without written consent from Product Owner unless Manufacturer notifies Product Owner in writing at least one hundred and twenty (120) calendar days prior to any such change. Any such change shall not apply to any Products sold to or ordered by Product Owner prior to the change. Product Owner will not alter the Limited Warranty, warranty disclaimers and limitation of liability without the prior written authorization of Manufacturer, nor extend or make any additional warranty or representation regarding the Products unless expressly authorized by Manufacturer.

 

THE LIMITED WARRANTY REFERRED TO IN THIS SECTION IS THE ONLY WARRANTY, EXPRESS OR IMPLIED, THAT MANUFACTURER MAKES WITH RESPECT TO THE PRODUCTS. MANUFACTURER SPECIFICALLY DISCLAIMS ALL OTHER IMPLIED WARRANTIES INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT.

 

B. Warranty Claims. The Limited Warranty is effective only if Product Owner gives prompt written notice to Manufacturer of any alleged breach of the Limited Warranty, which notice shall specifically describe the problem and shall state the date of sale and name and location of the recipient of the Product originally shipped by Manufacturer. Notwithstanding anything to the contrary contained herein, Manufacturer shall have no obligation under the Limited Warranty unless it receives such notice within thirty (30) days following the expiration of the warranty period. In the event of any breach of the Limited Warranty Manufacturer’s sole obligation is to replace each non-conforming Product within a reasonable period of time and to pay for the costs of shipment to the original recipient of the Product or as otherwise specified by Product Owner.

 

 

 

 

C. Recall. In the event that: (i) any applicable federal, state or foreign regulatory authority should issue a request, directive or order that a Product be recalled; (ii) a court of competent jurisdiction orders such a recall or; (iii) Manufacturer determines that the Product represents a risk of injury or customer deception or is otherwise defective and that the recall of a Product is appropriate (“Recall”), Manufacturer shall have sole right and responsibility for implementing the Recall. Product Owner will provide cooperation and assistance to Manufacturer in connection therewith, as may be reasonably requested by Manufacturer. Manufacturer shall be solely responsible for all expenses affecting such Recall (including any reasonable out-of-pocket expenses incurred by Product Owner in connection with such cooperation, as directed in writing by Manufacturer).

 

7. INDEMNIFICATION.

 

A. Indemnity Obligations for Intellectual Property Infringement. Manufacturer agrees to defend, indemnify and hold harmless Product Owner from and against any and all claims, losses, damages, suits, expenses (including reasonable attorneys’ fees) and costs (collectively “Claims”) brought or alleged by a third party that the Manufacturer IP or any Products sold to Product Owner infringe any U.S. patent, trademark or copyright. Product Owner shall reasonably cooperate with Manufacturer, its insurance company and its legal counsel in its defense of such Claims. If the use or sale of any Products furnished under this Agreement is enjoined as a result of a Claim, Manufacturer shall either obtain on behalf of the Product Owner the right to continue to use or sell such Products, substitute an equivalent product reasonably acceptable to Product Owner in its place, or reimburse Product Owner the purchase price of the Products, costs incurred by Product Owner as a result of such cancellation, and any and all losses or costs incurred as a result of Product Owner’s breach of any purchaser order or other agreement with its customers. Notwithstanding the foregoing, this indemnity shall not apply or cover any Claims based upon any infringement or alleged infringement of any patent, trademark or copyright resulting from the alteration or unauthorized (by Manufacturer) use of any Manufacturer IP or Products by Product Owner or a Product Owner representative or the combination of any Products with any other products or the combination of any Manufacturer IP with any other mark, if such infringement claim would have been avoided but for such alteration, combination or unauthorized use by Product Owner or any Product Owner representative. Product Owner shall also have the right to participate in the defense of any such action and have the right to hire its own legal counsel at Product Owner’s expense. This indemnity shall not cover any Claims in which Product Owner fails to provide Manufacturer with prompt written notice of the Claim which lack of notice materially prejudices the defense of the Claim.

 

B. Manufacturer’s Additional Indemnity Obligations. Notwithstanding anything herein to the contrary, in addition to all other rights and remedies available at law or in equity, Manufacturer hereby agrees to defend, indemnify and hold harmless Product Owner from and against any and all third party Claims (i) arising out of any defects in any Products existing at the time such Products are sold by Manufacturer to Product Owner, or (ii) arising out of the negligent acts or omissions or willful misconduct of Manufacturer, its employees, agents or representatives with respect to the Products or its performance of this Agreement. Product Owner shall reasonably cooperate with Manufacturer, its insurance company and its legal counsel in its defense of such Claims. Product Owner shall also have the right to participate in the defense of any such action and have the right to hire its own legal counsel at Product Owner’s expense. This indemnity shall not cover any Claims in which Product Owner fails to provide Manufacturer with prompt written notice of the Claim which lack of notice materially prejudices the defense of the Claim.

 

 

 

 

C. Product Owner’s Indemnity Obligations to Manufacturer. Product Owner hereby agrees to defend, indemnify and hold harmless Manufacturer, its affiliates and their respective officers directors, employees and agents from and against any and all Claims (i) arising out of the negligent acts or omissions or willful misconduct of Product Owner, its employees, agents or representatives with respect to its performance of this Agreement, sale of Products, or otherwise, (ii) arising out of the alteration or modification of the Products or Manufacturer IP by Product Owner or its employees, agents or representatives, or (iii) alleging that the Product Owner’s Marks infringe or otherwise violate the intellectual property rights of a third party. This indemnity shall not cover any Claims in which Manufacturer fails to provide Product Owner with prompt written notice which lack of notice prejudices the defense of the Claim. Manufacturer shall also have the right to participate in the defense of any such action and have the right to hire its own legal counsel at Manufacturer’s expense.

 

D. Settlement of Claims. In no event shall a party seeking or entitled to indemnification from a Party hereunder settle, compromise, agree to a judgment or take any similar action with respect to any Claim without the written consent of the Party from whom indemnification is sought.

 

8. LIMITATION OF LIABILITY.

 

EXCEPT FOR THE PARTIES’ INDEMNIFICATION OBLIGATIONS UNDER SECTION 8 OF THIS AGREEMENT AND CONFIDENTIALITY OBLIGATIONS UNDER SECTION 5 OF THIS AGREEMENT, IN NO EVENT SHALL EITHER PARTY BY LIABLE UNDER THIS AGREEMENT TO THE OTHER PARTY FOR ANY INCIDENTAL, CONSEQUENTIAL, INDIRECT, STATUTORY, SPECIAL, OR PUNITIVE DAMAGES, INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF USE, LOSS OF TIME, INCONVENIENCE, LOSS BUSINESS OPPORTUNITIES, DAMAGE TO GOOD WILL OR REPUTATION, OR LOSS OF DATA, REGARDLESS OF WHETHER SUCH LIABILITY IS BASED ON BREACH OF CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, AND EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES OR SUCH DAMAGES COULD HAVE BEEN REASONABLY FORESEEN.

 

9. TERM. This Agreement shall commence on the Effective Date and shall end on the tenth anniversary of the Effective Date (the “Initial Term”) unless earlier terminated pursuant to Section 11 hereof. The Initial Term shall automatically renew for successive renewal terms of five (5) years each (each, a “Renewal Term”), unless either Party provides the other Party with written notice of its intention not to renew the Initial Term or any Renewal Term, as applicable, at least sixty (60) days prior to the expiration of the then current Initial Term or Renewal Term.

 

10. TERMINATION.

 

A. Termination for Breach. Either Party may terminate this Agreement at any time in the event of a material breach by the other Party that remains uncured after thirty (30) calendar days following written notice thereof. Such termination shall be effective immediately and automatically upon the expiration of the applicable notice period, without further notice or action by either Party. Termination shall be in addition to any other remedies that may be available to the non-breaching Party.

 

 

 

 

B. Termination for Financial Insecurity. Either Party may terminate this Agreement and any outstanding Purchase Orders (to the extent Products have not already been delivered to the carrier for shipment) immediately at its option upon written notice if the other Party: (i) becomes or is declared insolvent or bankrupt; (ii) is the subject of a voluntary or involuntary bankruptcy or other proceeding related to its liquidation or solvency, which proceeding is not dismissed within sixty (60) calendar days after its filing; (iii) ceases to do business in the normal course; or (iv) makes an assignment for the benefit of creditors. This Agreement shall terminate immediately and automatically upon any determination by a court of competent jurisdiction that either Party is excused or prohibited from performing in full all obligations hereunder, including, without limitation, rejection of this Agreement pursuant to 11 U.S.C. §365.

 

C. Obligations upon Termination. Upon termination of this Agreement, Product Owner shall cease to be an authorized reseller of the Products and shall have no right to use Manufacturer’s IP other than in connection with the liquidation of Product on hand or received after the date of termination and (i) all unaccepted Purchase Orders may be cancelled by Product Owner or Manufacturer without liability, and (ii) Product Owner may, at its option, resell and deliver to Manufacturer, free and clear of all liens and encumbrances, any or all Products that (A) are subject to Purchase Orders accepted by Manufacturer whether or not the applicable Products have been shipped as of the date of termination and (B) were manufactured, shipped or received as of the date of termination, in each case that are in new condition and in the original factory packaging at the original purchase price of any such Products that Product Owner elects to resell to Manufacturer less a restocking charge of 50% of such amount payable by Manufacturer upon receipt of such Products. Restocking is waived in the event the Manufacturer terminates Product Owner, other than if termination is a Termination for Breach as outlined in 10.A. Within ninety (90) calendar days of termination of this Agreement, Product Owner shall remove and not thereafter use any sign, display, or other advertising or marketing means containing Manufacturer Marks, except as provided in this section. Product Owner may continue to use in-store materials containing the Manufacturer’s IP as reasonably required for the resale of the Products which may be remaining in Product Owner’s possession after termination, which materials Product Owner may continue to utilize until all remaining Products have been sold or one hundred eighty (180) calendar days after termination, whichever comes first, after which Product Owner shall cease the use of any such Manufacturer IP.

 

11. COMPLIANCE WITH LAWS. Product Owner acknowledges and understands that the Products may be subject to restrictions upon export from the United States and upon resale after export. Product Owner therefore represents and warrants that it shall comply fully with all relevant regulations of the U.S. Department of Commerce, with the U.S. Export Administration Act, and with any other import and/or export control laws or regulations of the United States or any other jurisdiction.

 

12. GENERAL TERMS.

 

A. Independent Contractors. Nothing in this Agreement, and no course of dealing between the Parties, shall be construed to create or imply an employment or agency relationship or a partnership or joint venture relationship between the Parties or between one Party and the other Party’s employees or agents. Neither Manufacturer nor Product Owner has the authority to bind the other, to incur any liability or otherwise act on behalf of the other. Each Party shall be solely responsible for payment of its employees’ salaries (including withholding of income taxes and social security), workers compensation, and all other employment benefits.

 

 

 

 

B. Assignment. Neither this Agreement, nor any right or interest herein, may be assigned, in whole or in part, without the express written consent of the other Party. Any assignment without such consent shall be null and void. Notwithstanding the foregoing, the Product Owner may subcontract its rights or obligations under this Agreement with the prior written consent of Manufacturer. Either party may assign this Agreement if the assignment is carried out as part of a merger, restructuring, or reorganization, or sale or transfer of all or substantially all of a Party’s assets. This Agreement shall be binding upon and inure to the benefit of the Parties hereto, their successors and legal representatives. Except as set forth in Section 8, there are no third-party beneficiaries to this Agreement.

 

C. Notices. Unless otherwise agreed to by the Parties, all notices shall be deemed effective when received and made in writing by either (i) certified mail, return receipt requested, (ii) nationally recognized overnight courier, or (iii) fax with confirmation, addressed to the party to be notified at the following address or to such other address as such Party shall specify by like notice hereunder:

 

If to Manufacturer:

MEDSCIENCE RESEARCH GROUP, INC.

16469 BRIDLEWOOD CIR

DELRAY BEACH, FL 33445

  Attn: MEDSCIENCE - CORPORATE
  Email:

[***]

  Fax: 561-258-0533

 

If to Product Owner:

 

USA EQUITIES CORP

901 Northpoint Parkway, Suite 302.

WEST PALM BEACH, FL 33407

  Attn: USA EQUITIES CORP - CORPORATE
  Email:

[***]

  Fax: 561-258-0533

 

(with a copy to, which does not serve as notice):

 

Mandelbaum Salsburg Attorneys at Law

1270 Avenue of the Americas

Suite 1808

NEW YORK, NY 10020

Attn: VINCENT McGILL

Email: [***]

Fax: 917-383-1228

 

Either Party, by written notice to the other pursuant to this section, may change its address or designees for receiving such notices.

 

D. Force Majeure. Neither Party shall liable hereunder for any failure or delay in the performance of its obligations under this Agreement if such failure or delay is on account of causes beyond its control, including labor disputes, civil commotion, war, fires, floods, inclement weather, governmental regulations or controls, casualty, government authority, strikes, or acts of God, in which event the non-performing party shall be excused from its obligations for the period of the delay and for a reasonable time thereafter. Each Party shall use reasonable efforts to notify the other Party of the occurrence of such an event within three (3) business days of its occurrence.

 

 

 

 

E. Governing Law; Venue; Jury Waiver. This Agreement shall be governed by the laws of the State of Florida, without giving effect to the principles of conflicts of law of such state and shall be binding upon the Parties hereto in the United States and worldwide. Any claims or legal actions by one Party against the other arising under this Agreement or concerning any rights under this Agreement shall be commenced and maintained in any state or federal court located in Palm Beach County, Florida. Both Parties hereby submit to the jurisdiction and venue of any such court. THE PARTIES FURTHER AGREE, TO THE EXTENT PERMITTED BY APPLICABLE LAW, TO WAIVE ANY RIGHT TO TRIAL BY JURY WITH RESPECT TO ANY CLAIM, COUNTERCLAIM OR ACTION ARISING FROM THE TERMS OF THIS AGREEMENT.

 

F. Attorney’s Fees. If either Party incurs any legal fees associated with the enforcement of this Agreement or any rights under this Agreement, the prevailing Party shall be entitled to recover its reasonable attorney’s fees and any court, arbitration, mediation, or other litigation expenses from the other Party.

 

G. Survival. The provisions of this Agreement which by their sense and context should survive any termination of expiration of this Agreement, including without limitation sections 4 (confidentiality), 6 (warranty), 7 (indemnification), 8 (limitation of liability), 11 (compliance with laws) and 12 (general terms) shall so survive.

 

H. Authorized Signatories. It is agreed and warranted by the Parties that the individuals singing this Agreement on behalf of the respective Parties are authorized to execute such an agreement. No further proof of authorization shall be required.

 

I. Severability. If any provision or portion of this Agreement shall be held by a court of competent jurisdiction to be illegal, invalid, or unenforceable, the remaining provisions or portions shall remain in full force and effect.

 

J. No Strict Construction. This Agreement shall not be construed more strongly against either party regardless of which party is more responsible for its preparation.

 

K. Counterparts. This Agreement may be executed by facsimile and in one or more counterparts, each of which will be deemed to be an original, but all of which together will constitute one and the same instrument, without necessity of production of the others.

 

L. Entire Agreement; Modification; Waiver. This Agreement is the entire agreement between the Parties with respect to the subject matter and supersedes any prior agreement or communications between the Parties hereto, whether written or oral. This Agreement may be modified only by a written amendment signed by authorized representatives of both Parties. No waiver of any term or right in this Agreement shall be effective unless in writing, signed by an authorized representative of the waiving Party. The failure of either Party to enforce any provision of this Agreement shall not be construed as a waiver or modification of such provision, or impairment of its right to enforce such provision thereafter.

 

[SIGNATURES ON FOLLOWING PAGE]

 

 

 

 

IN WITNESS WHEREOF, the parties hereto have caused this Distribution Agreement to be duly executed by their duly authorized representatives as of the Effective Date.

 

  MANUFACTURER
     
  MEDSCIENCE RESEARCH GROUP, INC.
     
  By: /s/ Marvin Smollar
  Name: Marvin Smollar
  Title: Senior Manager
     
  PRODUCT OWNER
     
  USA EQUITIES CORP.
     
  By: /s/ Troy Grogan
  Name: Troy Grogan
  Title: Chief Executive Officer

 

 

 

 

Exhibit A

 

The Product Owner’s Product Pricing from Manufacturer is as follows:

 

Item 4200, the complete AllergiEnd 42 test Kit (Environmental)…………..….. [***]

 

Item 3600, the complete AllergiEnd 42 test Kit (Food)……..………………..….. [***]

 

Item 1038, AllergiEnd Low Dose Sublingual Immunotherapy (SLIT) Unit.......... [***]

 

Item 1039, AllergiEnd Maintenance Dose Sublingual Immunotherapy (SLIT) Unit[***]

 

Item 3007 to 3008 Allergen Subcutaneous Injectable Mixtures (SCIT) per 46 dose set [***]

 

Item 3009 Allergen Subcutaneous Injectable Maintenance 12 Dose vial [***]

 

 

 

 

 

Exhibit 99.1

 

 

USA Equities Corp. Acquires AllergiEnd®Assets

 

  Acquisition Strengthens USAQ Business Model and Strategic Position
  Purchase includes AllergiEnd® Method Patent, Trademark and Website
  AllergiEnd®’s Product Portfolio Favorably Aligned with Industry Growth Drivers and Trends

 

West Palm Beach, FL – June 24, 2021 – USA Equities Corp. (OTCQB: USAQ), a company focused on value-based healthcare solutions and physician-directed digital medicine, today announced it has acquired the method patent, trademark and website associated with AllergiEnd®’s diagnostic and allergen immunotherapy product portfolio from MedScience Research Group, Inc.

 

“We continue to strengthen our growing medical device technology and software platform with today’s announced acquisition of the AllergiEnd® intellectual properties. These properties are a great strategic fit that further support our recurring revenue business model focused on non-specialist medical practitioners, which is a large and growing addressable market. We are very well positioned in this market given our deep applications expertise and industry relationships,” said Troy Grogan, CEO of USA Equities Corp.

 

“AllergiEnd®’’s FDA-cleared diagnostic equipment and products allow primary care providers to diagnose and treat many common chronic allergies in their offices. In particular, the number of people in the U.S. affected by allergic disorders, currently estimated to be 60 million, is expected to grow at a double-digit rate while the number of full-time-equivalent allergists and immunologists is expected to decline. In addition to addressing these secular trends and enhancing patient quality of life, AllergiEnd® treatment solutions are also reimbursable from Medicare and commercial insurance providers, further driving revenue opportunities for physicians in their own practices.

 

“The acquisition of the AllergiEnd® assets also provides USAQ the opportunity to more fully integrate and leverage the product portfolio across our marketing platform, customer relationships and cost structure, which we expect will facilitate improvement in our margin profile over time. Finally, our pipeline of organic growth opportunities remains active and focused on expanding our distribution channels and product portfolio,” concluded Grogan

 

About USA Equities Corp.

 

USA Equities Corp. (OTCQB: USAQ) is focused on providing value-based healthcare solutions, clinical informatics and algorithmic personalized medicine including digital therapeutics, behavior-based remote patient monitoring, chronic care and preventive medicine. The Company’s products are intended to allow general practice physicians and other medical practitioners to increase revenues by cost effectively diagnosing and treating chronic diseases that are generally referred to specialists. The Company’s products and information service portfolio are directed toward prevention, early detection, management and reversal of allergies, cardio-metabolic and other chronic diseases. Our principal objectives are to develop proprietary software tools, point of care devices and approaches, providing more granular, timely and specific clinical decision-making information for practicing physicians and other health care providers to address today’s allergy prone, obese, diabetic and cardiovascular diseased populations.

 

For additional information, visit the Company’s website at www.USAQCorp.com

 

 

 

 

Forward-Looking Statements

 

Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products and potential future results and acquisitions, are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘targets’, ‘expects’, or ‘intends’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products and the acceptance of these products, the inherent discrepancy in actual results from estimates, projections and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

 

Investor & Media Contact:  
   
Olivia Giamanco  
USA Equities Corp  
(929) 379-6503  
IR@USAQCORP.COM